Vince
Super Moderator
Potential of a drug called XP-8121. This drug is a once-weekly subcutaneous injection of levothyroxine for hypothyroidism and has a total addressable market of over $1 billion. Current treatment for hypothyroidism requires daily oral pills taken on an empty stomach, which many patients struggle to adhere to or absorb properly. Xeris' product is a once-a-week injection that could revolutionize the standard of care for millions of patients. XP-8121 is currently Phase 3-ready, with the major trial expected to begin in the second half of 2026.
www.palomahealth.com
Once-Weekly Injectable Levothyroxine: A Future Hypothyroidism Treatment Option | Paloma Health
A weekly thyroid shot instead of daily pills? See how once-weekly levothyroxine could redefine future hypothyroidism care. . Learn more about hypothyroidism with Paloma Health
www.palomahealth.com
